Bayer AG (NASDAQ:BAYRY) has been assigned an average recommendation of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company.
Several research analysts have commented on the company. Zacks Investment Research downgraded Bayer AG from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Berenberg Bank downgraded Bayer AG from a “buy” rating to a “hold” rating in a report on Monday, July 3rd.
Bayer AG (BAYRY) traded down 0.553% during trading on Friday, hitting $124.975. The stock had a trading volume of 59,433 shares. The stock has a market capitalization of $108.99 billion and a PE ratio of 18.589. Bayer AG has a 12 month low of $91.53 and a 12 month high of $139.04.
Bayer AG (NASDAQ:BAYRY) last released its quarterly earnings data on Thursday, July 27th. The company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.87 by $0.12. The company had revenue of $13.41 billion for the quarter, compared to the consensus estimate of $14.45 billion. Bayer AG had a return on equity of 24.89% and a net margin of 16.40%. Analysts forecast that Bayer AG will post $9.09 EPS for the current fiscal year.
About Bayer AG
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with our FREE daily email newsletter.